Nanjing Drum Tower Hospital
南京鼓楼医院
Listed for 23 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Nanjing Drum Tower Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌2 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌13 papers led
- Hepatocellular carcinoma肝细胞癌95 papers led2 open trials led
- Stomach cancer胃癌113 papers led3 open trials led
- Osteosarcoma骨肉瘤8 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤12 papers led
- Neuroblastoma神经母细胞瘤1 paper led
- Multiple myeloma多发性骨髓瘤17 papers led
- Haemophilia A血友病 A2 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led
- Myasthenia gravis重症肌无力2 papers led
- Moyamoya disease烟雾病7 papers led
- Takayasu arteritis大动脉炎1 paper led
- Idiopathic pulmonary fibrosis特发性肺纤维化31 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
- Fabry disease法布雷病0 papers led
- Behçet disease白塞病0 papers led
- IgA nephropathyIgA 肾病3 papers led
- Osteogenesis imperfecta成骨不全症0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症0 papers led
- Hereditary angioedema遗传性血管性水肿1 paper led
Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 2 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.08%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Nanjing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)4
- 1372P A prospective, open and single-arm phase II clinical study of nab-paclitaxel combined with cisplatin and PD-1 inhibitor followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal
- Association of nutritional counselling with the severity of radiation-induced oral mucositis in patients with nasopharyngeal carcinoma: a retrospective study
- Beneficial role of customized intraoral stents in radiotherapy for nasopharyngeal carcinoma.
- MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 13 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Nanjing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led13
- Comparison of clinical and prognostic characteristics between superficial basaloid and conventional esophageal squamous carcinoma.
- Epigenetically-Upregulated CD98 Shed Light on the Precancerous Diagnosis and Prognosis Prediction of Esophageal Cancer.
- Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis.
- Incidence of MSI-H esophageal carcinoma and related identification of genomic alterations: A multi-center real-world study.
- Value of blood oxygenation level-dependent magnetic resonance imaging in early evaluation of the response and prognosis of esophageal squamous cell carcinoma treated with definitive chemoradiotherapy: a preliminary study.
- Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.
- Submucosal gland differentiation and implications in esophageal basaloid squamous cell carcinomas.
- Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids.
- Circ_0058063 regulates cell vitality and proliferation in oesophageal squamous-cell carcinomas.
- Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma.
- Association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study.
- Combined assessment of tumour cell nest size and desmoplastic reaction as an excellent prognostic predictor in oesophageal squamous cell carcinoma.
- A Novel Deep Learning System for Diagnosing Early Esophageal Squamous Cell Carcinoma: A Multicenter Diagnostic Study.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status4
- Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)10
- PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study
- The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-N
- Tislelizumab plus short-course chemo-radiotherapy for conversion therapy of unresectable ESCC (LATE): A proof-of-concept, phase Ib trial.
- Effect of PLCE1-driven aerobic glycolysis through ENO1 modulation on immune evasion in esophageal squamous cell carcinoma (ESCC).
- Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.
- Tagging polymorphisms in CTLA4 gene with esophageal squamous cell carcinomas: a case-control study
- 172P PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
- 325. THE ASSOCIATED RISK BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS OF AP1S1 AND ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINESE POPULATION
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- Preoperative chemotherapy combined with PD-1 inhibitor in locally advanced operable or potentially resectable esophageal squamous cell carcinoma: A real world study.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 95 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.6%.
- Open trials as a site
- 0
- led by another institution
7 hospitals in Nanjing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
- Phase
- Not given
- Started
- 2022-12
- Registry
- NCT05661786
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- Not yet recruitingFAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07314372
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led95
- Favourable Prognosis of Patients With Untreated HBeAg-Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL.
- The impact of an RNA-binding protein group on regulating the RSPO-LGR4/5-ZNRF3/RNF43 module and the immune microenvironment in hepatocellular carcinoma.
- BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.
- Villin1 predicts survival and adjuvant TACE response in hepatocellular carcinoma.
- SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy.
- RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA.
- S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway.
- Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues.
- Concurrent and predictive validity of the Global Leadership Initiative on Malnutrition (GLIM) criteria in patients with advanced hepatocellular carcinoma receiving systemic therapy.
- MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance.
- Bioinformatics analysis and experimental studies reveal KPNA2 as a novel biomarker of hepatocellular carcinoma progression and telomere maintenance.
- Fat fraction quantification by MRI predicts diagnosis and prognosis of HBV-related steatohepatitic hepatocellular carcinoma.
- Differential HCC risk among HBV indeterminate types at baseline and by phase transition.
- Pathological study of the tumor microenvironment after neoadjuvant therapy in hepatocellular carcinoma: Difference of TACE combined with antiangiogenics and immunotherapy.
- Improved Hypoxic Microenvironment By Nanoformulation For Effective T Cell Therapy In Mice Model.
- KBTBD8/RRP15 as a potential novel therapeutic target associates with lenvatinib-inhibited progression in hepatocellular carcinoma both in vitro and in vivo.
- GSTK1 suppresses HCC aggravation via L-carnitine metabolism by PGAM5/DRP1 complex-mediated mitochondrial quality control.
- Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression.
- ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma.
- RNA nanotherapeutics for hepatocellular carcinoma treatment.
- Apolipoprotein A1-encoding recombinant adenovirus remodels cholesterol metabolism in tumors and the tumor microenvironment to inhibit hepatocellular carcinoma.
- Composite Microparticles from Microfluidics for Chemo-/Photothermal Therapy of Hepatocellular Carcinoma.
- Letter: Association of persistently high HBsAg levels during HBeAg-seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients.
- Cascading Detection of Hydrogen Sulfide and N-Acetyltransferase 2 in Hepatocellular Carcinoma Cells Using a Two-Photon Fluorescent Probe.
- Early-life antibiotic exposure aggravate the metabolic dysfunction-associated steatotic liver disease associated hepatocellular carcinoma.
- N6-methyladenosine (m6A) modification in hepatocellular carcinoma.
- β-Catenin Activation Reprograms Ammonia Metabolism to Promote Senescence Resistance in Hepatocellular Carcinoma.
- MVP enhances FGF21-induced ferroptosis in hepatocellular carcinoma by increasing lipid peroxidation through regulation of NOX4.
- Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial.
- Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA.
- Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
- Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma.
- Biohybrid hydrogel inhibiting β-klotho/HDAC3 axis for hepatocellular carcinoma treatment.
- HOXA9 promotes proliferation, metastasis and prevents apoptosis in hepatocellular carcinoma.
- Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma.
- DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway.
- Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma.
- In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response.
- Current research insights into the role of CTLA-4 in hepatitis B virus (HBV) infection.
- CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma.
- Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.
- Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
- HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway.
- Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
- Long noncoding RNA SNHG4 promotes the malignant progression of hepatocellular carcinoma through the miR-211-5p/CREB5 axis.
- CFDP1 promotes hepatocellular carcinoma progression through activating NEDD4/PTEN/PI3K/AKT signaling pathway.
- UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
- FOXO1 regulates Th17 cell-mediated hepatocellular carcinoma recurrence after hepatic ischemia-reperfusion injury.
- Oxoglutarate dehydrogenase-like inhibits the progression of hepatocellular carcinoma by inducing DNA damage through non-canonical function.
- Immunotherapy for hepatocellular carcinoma.
- Systematic profiling of a lipid metabolism-derived signature guides risk-stratification and therapeutic strategies in hepatocellular carcinoma.
- Targeting WDxR motif reprograms immune microenvironment and inhibits hepatocellular carcinoma progression.
- LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
- NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway.
- Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.
- How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data.
- Aberrant acetylated modification of FGF21‑KLB signaling contributes to hepatocellular carcinoma metastasis through the β‑catenin pathway.
- A commentary on 'Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: a retrospective cohort study' ( Int J Surg 2
- A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.
- The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma.
- A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.
- Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma.
- Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells.
- iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
- Liquid Biopsy in Hepatocellular Carcinoma.
- A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study.
- Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase.
- Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma.
- Knockdown of lncRNA HAGLROS inhibits metastasis and promotes apoptosis in nephroblastoma cells by inhibition of autophagy.
- Association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study.
- GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
- An automated, rapid fluorescent immunoassay to quantify serum soluble programmed death-1 (PD-1) protein using testing-on-a-probe biosensors.
- Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis.
- Radiomics Analysis on Noncontrast CT for Distinguishing Hepatic Hemangioma (HH) and Hepatocellular Carcinoma (HCC).
- The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody.
- Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis.
- Letter to the Editor: Is HBV genotype strongly associated with HCC risk in patients with chronic hepatitis B?
- Tumor-Promoting Actions of HNRNP A1 in HCC Are Associated with Cell Cycle, Mitochondrial Dynamics, and Necroptosis.
- HBV Infection-Related PDZK1 Plays an Oncogenic Role by Regulating the PI3K-Akt Pathway and Fatty Acid Metabolism and Enhances Immunosuppression.
- The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription.
- Prognostic value of protein biomarkers in liver transplantation: A systematic review.
- Extracellular HMGB1 promotes CD44 expression in hepatocellular carcinoma via regulating miR-21.
- Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
- Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
- Circular RNA circ_0008274 upregulates granulin to promote the progression of hepatocellular carcinoma via sponging microRNA -140-3p.
- Inhibition of ribosomal RNA processing 15 Homolog (RRP15), which is overexpressed in hepatocellular carcinoma, suppresses tumour growth via induction of senescence and apoptosis.
- PRRX1 deficiency induces mesenchymal-epithelial transition through PITX2/miR-200-dependent SLUG/CTNNB1 regulation in hepatocellular carcinoma.
- Prognostic and predictive role of a metabolic rate-limiting enzyme signature in hepatocellular carcinoma.
- Hsa-circRNA-103809 Promotes Hepatocellular Carcinoma Development via MicroRNA-1270/PLAG1 Like Zinc Finger 2 Axis.
- Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
- Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report.
- The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation.
- Asiatic Acid Encapsulated Exosomes of Hepatocellular Carcinoma Inhibit Epithelial-Mesenchymal Transition Through Transforming Growth Factor Beta/Smad Signaling Pathway.
- TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.
- HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging.
Chinese-language papers (not in the count)2
- [New progress on diagnosis and treatment for indeterminate-phase chronic hepatitis B virus-infected patients].
- [Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate-and advanced-stage hepatocellular carcinoma with sec
All its trials on ClinicalTrials.gov, any status12
- FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
- Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
- Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image
- Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
- Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
- NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
- GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
- Clinical Characteristics of Primary Liver Cancer
- The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After Hepatectomy
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Cancer
Stomach cancer
胃癌Led 113 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.2%.
8 hospitals in Nanjing for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 10
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07298200
Age 18 years to 70 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingLow-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06791148
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingTislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05687357
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07789184
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingSafety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
- Phase
- Early phase 1
- Started
- 2025-10
- Registry
- NCT07166263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingClinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06128252
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- Not yet recruitingLymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07902596
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led113
- Dual-energy CT to evaluate the infiltration status of tumor-associated macrophage (TAM) in gastric cancer: a preliminary study.
- A nomogram model based on CT-assessed body composition parameters for predicting postoperative recurrence in advanced gastric cancer.
- Clinicopathologic and molecular mutational analysis of inflammatory fibroid polyps.
- RBM8A confers oxaliplatin resistance in gastric cancer by maintaining EGFR mRNA stability.
- Efficacy and safety of subserosal versus submucosal carbon nanoparticle-guided laparoscopic radical gastrectomy (DANCE-04): A randomized clinical trial.
- Dual-energy CT for predicting serosal invasion in gastric cancer and subtype analysis.
- Changes of bone, adipose, and muscle-related body compositions in gastric cancers after gastrectomy using deep learning based automatic segmentation.
- A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study.
- Inflammatory and nutritional markers predict response and prognosis of patients with locally advanced gastric cancer receiving neoadjuvant immunochemotherapy.
- Clinical Characteristics, Prognostic Factors and Therapeutic Strategies in Gastric Cancer Patients With Bone Metastasis: A Retrospective Analysis.
- Identification of AXL as a novel positive regulator of lipid raft in gastric cancer.
- Expression Patterns of Immune Checkpoint Molecules and Their Clinical Values in Gastric Neuroendocrine Neoplasms.
- Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer.
- Circulating PD-1+ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer.
- A rapid ex vivo co-culture of memory-like NK and activated T cells enhances anti-tumor response in gastric cancer.
- Novel tetrameric bispecific KK-LC-1×CD16A-armed memory-like NK cells enhance antitumor efficacy in gastric cancer.
- Analysis of clinicopathologic characteristics and risk factors for missed diagnosis in synchronous multiple early gastric cancer.
- Preoperative Prediction of Sarcopenia in Patients Scheduled for Gastric and Colorectal Cancer Surgery.
- Effects of perioperative ω-3 fish oil fat emulsion on postoperative gastric emptying function following Roux-en-Y reconstruction for gastric cancer.
- Long-term outcomes of additional surgery vs. observation after noncurative endoscopic submucosal dissection for early gastric cancer and application value of the eCura scoring system: a propensity score-matched study.
- Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer.
- Investigating the role of intratumoral Streptococcus mitis in gastric cancer progression: insights into tumor microenvironment.
- NNMT-mediated N6-methyladenosine modification of NR4A3 mRNA facilitates lymphatic metastasis of gastric adenocarcinoma.
- The strategy of vitamin supplementation in Chinese patients with gastric cancer after gastrectomy: a prospective cohort study.
- Impact of distal or pylorus preserving gastrectomy on postoperative quality of life in T1 stage middle third gastric cancer patients.
- DRAM1 enhances the proliferation and metastasis of gastric cancer through the PI3K/AKT/mTOR signaling pathway and energy metabolism.
- Machine learning-assisted washing-free detection of extracellular vesicles by target recycling amplification based fluorescent aptasensor for accurate diagnosis of gastric cancer.
- Pancreatic atrophy after gastric cancer surgery: influencing factors and effects on BMI and quality of life.
- Epstein-Barr virus positive gastric cancer: the pathological basis of CT findings and radiomics models prediction.
- Enhanced Photodynamic Therapy Synergizing with Inhibition of Tumor Neutrophil Ferroptosis Boosts Anti-PD-1 Therapy of Gastric Cancer.
- Red ginseng polysaccharide promotes ferroptosis in gastric cancer cells by inhibiting PI3K/Akt pathway through down-regulation of AQP3.
- Cross-talk between gastric cancer and hepatic stellate cells promotes invadopodia formation during liver metastasis.
- Sotos Syndrome with NSDI Gene Mutations and Li-Fraumeni Syndrome with TP53 Gene Mutations in a Patient with Multiple Gastric Signet-Ring Cell Carcinomas.
- Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer.
- Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer.
- Thirdhand smoke exposure promotes gastric tumor development in mouse and human.
- Case report: A case of advanced gastric cancer with multiple skin metastases, with significant relief from immunotherapy.
- Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design.
- Gastric Ganglioneuroblastoma in an Elderly man: A Case Report and Literature Review.
- Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world.
- NTRK gene alterations were enriched in hepatoid or enteroblastic differentiation type of gastric cancer.
- CircUSP1 as a novel marker promotes gastric cancer progression via stabilizing HuR to upregulate USP1 and Vimentin.
- Helicobacter pylori infection increases risk of bleeding during endoscopic submucosal dissection for early gastric cancer.
- Risk factors of missed early gastric cancer in endoscopic resected population: a retrospective, case-control study.
- A Superficial Spreading Type of Early Gastric Cancer Arising in Autoimmune Gastritis.
- The potential effect and mechanism of Saikosaponin A against gastric cancer.
- Risk factors of additional surgery after non-curative endoscopic submucosal dissection for early gastric cancer.
- Comparison of clinical and pathological features between early-stage gastric-type and intestinal-type differentiated adenocarcinoma: a retrospective study.
- Comparison of clinical outcomes and prognosis between surgery and endoscopic submucosal dissection in patients with synchronous multifocal early gastric cancer.
- CircRNA CDR1as: a novel diagnostic and prognostic biomarker for gastric cancer.
- Necroptosis Related Genes Predict Prognosis and Therapeutic Potential in Gastric Cancer.
- Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer.
- Genetic risk, metabolic syndrome, and gastrointestinal cancer risk: A prospective cohort study.
- Real-world clinical outcomes of the combination of anti-PD-1 antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer.
- Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
- Comparison of Modified Cap-Assisted Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection in Treating Intraluminal Gastric Gastrointestinal Stromal Tumor (≤20 mm).
- Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Intermediate-Risk Primary Gastric Gastrointestinal Stromal Tumors.
- Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case-control study.
- NNMT enriches for AQP5+ cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma.
- Gastrointestinal: A case of type 1 gastric neuroendocrine tumor with multiple endocrine neoplasia type 1.
- Subserosal Indocyanine Green Plus Submucosal Carbon Nanoparticle Navigated Laparoscopic Gastrectomy (DANCE-01): a Cohort Study.
- Determination of polyamines in urine via electrospun nanofibers-based solid-phase extraction coupled with GC-MS and application to gastric cancer patients.
- Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.
- ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways.
- H19 encourages aerobic glycolysis and cell growth in gastric cancer cells through the axis of microRNA-19a-3p and phosphoglycerate kinase 1.
- Mixed Histologic Type is a Risk Factor for Lymph Node Metastasis in Submucosal Invasive Early Gastric Cancer.
- Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.
- Dual tracer navigation for lymph node dissection in laparoscopic radical gastrectomy (DANCE trial): a protocol for a prospective, randomized clinical trial.
- Establishment and verification of prediction model of occult peritoneal metastasis in advanced gastric cancer.
- Prognostic analysis of 2-5 cm diameter gastric stromal tumors with exogenous or endogenous growth.
- Clinicopathological features and CT findings of papillary gastric adenocarcinoma.
- APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly.
- Application of preoperative CT texture analysis in papillary gastric adenocarcinoma.
- Integrative analysis of the proteome and transcriptome in gastric cancer identified LRP1B as a potential biomarker.
- A novel active mitochondrion-selective fluorescent probe for the NIR fluorescence imaging and targeted photodynamic therapy of gastric cancer.
- DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer.
- A Retrospective Cohort Study of Factors Influencing Lymph Node Metastasis in Patients With Early Gastric Papillary Adenocarcinoma.
- An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.
- Associations of Education Level With Survival Outcomes and Treatment Receipt in Patients With Gastric Adenocarcinoma.
- Predictive Factors for Acute Postoperative Pain After Open Radical Gastrectomy for Gastric Cancer.
- Comparison of endoscopic full-thickness resection and cap-assisted endoscopic full-thickness resection in the treatment of small (≤1.5 cm) gastric GI stromal tumors.
- Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.
- Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
- C-Reactive Protein/Albumin Ratio on the First Day after Surgery Predicts Short-Term Complications of Gastrectomy for Gastric Cancer.
- Development and validation of multivariate models integrating preoperative clinicopathological and radiographic findings to predict HER2 status in gastric cancer.
- A deep learning-based model improves diagnosis of early gastric cancer under narrow band imaging endoscopy.
- Comparison of short-term outcomes between robotic-assisted and laparoscopic gastrectomy guided by carbon nanoparticle suspension injection in gastric cancer.
- Preoperative T2-weighted MR imaging texture analysis of gastric cancer: prediction of TNM stages.
- Development and Validation of Multivariate Models Integrating Preoperative Clinicopathological Parameters and Radiographic Findings Based on Late Arterial Phase CT Images for Predicting Lymph Node Metastasis in Gastric Cancer.
- Naturally occurring aesculetin coumarin exerts antiproliferative effects in gastric cancer cells mediated via apoptotic cell death, cell cycle arrest and targeting PI3K/AKT/M-TOR signalling pathway.
- ASO Author Reflections: Comparison of Three Lymph Node Staging Systems for Prognostic Evaluation of Resected Gastric Adenocarcinoma.
- Prediction of serosal invasion in gastric cancer: development and validation of multivariate models integrating preoperative clinicopathological features and radiographic findings based on late arterial phase CT images.
- Clinicopathological significance of HSP70 expression in gastric cancer: a systematic review and meta-analysis.
- Clinical outcomes of early gastric cardiac cancer treated with endoscopic submucosal dissection in patients with different indications.
- Controlling Nutritional Status (CONUT) score as a predictive marker for short-term complications following gastrectomy of gastric cancer: a retrospective study.
- Risk factors for lymph node metastasis in gastric neuroendocrine tumor: a retrospective study.
- UBE2C mRNA expression controlled by miR-300 and HuR determines its oncogenic role in gastric cancer.
- Circular RNAs emerge as important regulators with great potential for clinical application in gastric cancer.
- Identification of a peptide binding to cancer antigen Kita-kyushu lung cancer antigen 1 from a phage-display library.
- Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT.
- Lipophilic recombinant-protein insertion endows lymphocytes with enhanced targeting-infiltration ability in EGFR positive cancer.
- Apolipoprotein C-II induces EMT to promote gastric cancer peritoneal metastasis via PI3K/AKT/mTOR pathway.
- Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?
- OSI-027 Alleviates Oxaliplatin Chemoresistance in Gastric Cancer Cells by Suppressing P-gp Induction.
- A deep learning-based system for identifying differentiation status and delineating the margins of early gastric cancer in magnifying narrow-band imaging endoscopy.
- Gastric poorly cohesive carcinoma: differentiation from tubular adenocarcinoma using nomograms based on CT findings in the 40 s late arterial phase.
- RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription.
- Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: an exploration of histogenesis, molecular characteristics, and prognostic markers.
- Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
- FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma.
- The Addition of ω-3 Fish Oil Fat Emulsion to Parenteral Nutrition Reduces Short-Term Complications after Laparoscopic Surgery for Gastric Cancer.
- Anoikis resistant gastric cancer cells promote angiogenesis and peritoneal metastasis through C/EBPβ-mediated PDGFB autocrine and paracrine signaling.
- The short-term and long-term outcomes of indocyanine green tracer-guided laparoscopic radical gastrectomy in patients with gastric cancer.
Chinese-language papers (not in the count)8
- [Consistency of claudin 18.2 expression with antibodies of different clones in gastric adenocarcinoma].
- [Application of PMS2 and MSH6 double-antibody detection in screening of mismatch repair deficient tumors].
- [Exploration of biomarkers for the efficacy of anti-PD-1 immunotherapy in patients with gastric cancer peritoneal metastasis].
- [Clinicopathological and molecular features of two cases of early gastric adenocarcinoma with enteroblastoid differentiation treated by endoscopic submucosal dissection].
- [Clinicopathological features of gastric carcinomas with NTRK-rearrangement/amplification: report of four cases].
- [Comparison of quality-of-life after proximal gastrectomy with double tract reconstruction versus gastric tube reconstruction in patients with proximal gastric cancer].
- [Skip metastasis at the esophageal resection margin in radical gastrectomy: clinical characteristics of 30 cases].
- [Accurate diagnosis and individualized treatment of advanced gastric cancer: pathological detection of biomarkers based on cancer tissue samples].
All its trials on ClinicalTrials.gov, any status27
- Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
- Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients
- Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC
- Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
- Pulsed Low Dose Rate Radiation Therapy for Gastric Cancer Patients With Peritoneal Metastasis
- PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
Cancer
Osteosarcoma
骨肉瘤Led 8 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
25 hospitals in Nanjing for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- Osteosarcoma Cell-Derived Migrasomes Promote Macrophage M2 Polarization to Aggravate Osteosarcoma Proliferation and Metastasis.
- Identification of effective anti-osteosarcoma agents via screening of an in-house NQO1-targeted compound library.
- Intelligent drug codelivery platform for immune microenvironment reconstruction and immunochemotherapy in osteosarcoma treatment.
- Doxorubicin-Loaded Microalgal Delivery System for Combined Chemotherapy and Enhanced Photodynamic Therapy of Osteosarcoma.
- Long noncoding RNA TUG1 promotes malignant progression of osteosarcoma by enhancing ZBTB7C expression.
- C-C Motif Chemokine Ligand 5 (CCL5): A Potential Biomarker and Immunotherapy Target for Osteosarcoma.
- USP48 alleviates bone cancer pain and regulates MrgC stabilization in spinal cord neurons of male mice.
- ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression.
Earlier papers (2016–2020)7
- The therapeutic value of the SphK1-targeting microRNA-3677 in human osteosarcoma cells.
- Clinical Outcome of Free Vascularized Fibula Graft in the Surgical Treatment of Extremity Osteosarcoma.
- Evaluation of sleep quality in adolescent patients with osteosarcoma using Pittsburgh Sleep Quality Index.
- Genetic Variant of NFIB is Associated With the Metastasis of Osteosarcoma in Chinese Population.
- CEP55 promotes the proliferation and invasion of tumour cells via the AKT signalling pathway in osteosarcoma.
- Reconstruction of bone defect with allograft and retrograde intramedullary nail for distal tibia osteosarcoma.
- Positive feedback regulation between microRNA-132 and CREB in spinal cord contributes to bone cancer pain in mice.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 12 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 2.3%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Nanjing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led12
- Huaier inhibits the proliferation and migration of gastrointestinal stromal tumors by regulating the JAK2 / STAT3 signaling pathway.
- Clinical characteristics and prognostic analysis of postoperative recurrence or metastasis of low-risk gastrointestinal stromal tumors.
- Controlling Nutritional Status (CONUT) score as a prognostic marker for gastrointestinal stromal tumours.
- Prognostic significance of serum CA125 in the overall management for patients with gastrointestinal stromal tumors.
- Comparison of Modified Cap-Assisted Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection in Treating Intraluminal Gastric Gastrointestinal Stromal Tumor (≤20 mm).
- Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Intermediate-Risk Primary Gastric Gastrointestinal Stromal Tumors.
- Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case-control study.
- KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients.
- Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2.
- Prognostic analysis of 2-5 cm diameter gastric stromal tumors with exogenous or endogenous growth.
- Comparison of endoscopic full-thickness resection and cap-assisted endoscopic full-thickness resection in the treatment of small (≤1.5 cm) gastric GI stromal tumors.
- Prognostic value of Onodera's nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)5
- Treatment options for giant gastrointestinal stromal tumours and related prognosis: a single-centre retrospective study.
- Retrospective Comparison of Endoscopic Full-Thickness Versus Laparoscopic or Surgical Resection of Small (≤ 5 cm) Gastric Gastrointestinal Stromal Tumors.
- Comparative clinical features and short-term outcomes of gastric and small intestinal gastrointestinal stromal tumours: a retrospective study.
- Texture analysis of CT images in predicting malignancy risk of gastrointestinal stromal tumours.
- The fourth space surgery: endoscopic subserosal dissection for upper gastrointestinal subepithelial tumors originating from the muscularis propria layer.
All its trials on ClinicalTrials.gov, any status1
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Nanjing for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 17 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Nanjing for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 10
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07258511
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07179679
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an
- RecruitingStudy of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-05
- Registry
- NCT06375044
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Phase
- Phase 4
- Started
- 2022-03
- Registry
- NCT05201781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05623020
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- Not yet recruitingA Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
- Phase
- Phase 1
- Started
- 2022-04
- Registry
- NCT05181501
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangzhou, Hefei, Nanjing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led17
- ZMYND8 Reads H3K36me2 to Activate CEBPE Transcription and Suppress Multiple Myeloma Progression through the Inhibition of Adaptive UPR Pathways.
- Identifying potential prognosis markers in relapsed multiple myeloma via integrated bioinformatics analysis and biological experiments.
- Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients.
- Leveraging diverse cellular stress patterns for predicting clinical outcomes and therapeutic responses in patients with multiple myeloma.
- A novel prognostic model based on pyroptosis-related genes for multiple myeloma.
- N6-methyladenosine regulators are potential prognostic biomarkers for multiple myeloma.
- CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation.
- Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma.
- Comparison of clinical features of multiple myeloma with paraosseous and extraosseous plasmacytoma in the era of novel drugs: a systemic review and meta-analysis.
- Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification.
- Formosanin C induces autophagy-mediated apoptosis in multiple myeloma cells through the PI3K/AKT/mTOR signaling pathway.
- Licochalcone A suppresses Sp1 expression with potential anti-myeloma activity.
- Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma.
- DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.
- PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
- Gene signatures and prognostic values of m6A-related genes in multiple myeloma.
- Metabolic markers for diagnosis and risk-prediction of multiple myeloma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status22
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Blood disorders
Haemophilia A
血友病 ALed 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Nanjing for haemophilia A160 hospitals in China for haemophilia A
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTo Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06833983
Age 18 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status5
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led no English-language PubMed papers on neuromyelitis optica spectrum disorder in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Nanjing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Myasthenia gravis
重症肌无力Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Nanjing for myasthenia gravis93 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Moyamoya disease
烟雾病Led 7 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 2.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Nanjing for moyamoya disease47 hospitals in China for moyamoya disease
No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led7
- Long-term clinical and radiological outcomes of extracranial-intracranial bypass in hemorrhagic patients with Moyamoya disease: A single-center observational study of 45 cases.
- The intraoperative hemodynamic and clinical research of three direct bypasses in moyamoya disease a prospective cohort of 98 cases.
- Enhanced blood vessel visualization and accelerated image acquisition using spiral magnetic resonance angiography in moyamoya disease: a comparative study with Cartesian magnetic resonance angiograhy.
- GM-CSF Promotes the Development of Dysfunctional Vascular Networks in Moyamoya Disease.
- Risk Factors for Cerebrovascular Events in Moyamoya Angiopathy Using 4D Flow MRI: A Pilot Study.
- Association of contrast enhancement of proximal internal carotid artery wall and champagne bottle neck sign with ipsilateral stroke in moyamoya disease patients.
- Recurrent hemorrhage risk associated with medial target medullary artery anastomosis from the periventricular collateral vessel in adult patients with moyamoya disease.
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)1
Other diseases
Takayasu arteritis
大动脉炎Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Nanjing for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 31 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
15 hospitals in Nanjing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07121413
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led31
- Integrin/CD44-targeted liposomes remodel the pulmonary microenvironment to alleviate acute exacerbation of pulmonary fibrosis.
- Targeting Senescent Alveolar Type 2 Cells with a Gene-Editable FePt Dual-Atom Catalyst for Mitigating Idiopathic Pulmonary Fibrosis.
- Histone methyltransferase KMT2A promotes pulmonary fibrogenesis via targeting pro-fibrotic factor PU.1 in fibroblasts.
- Nomogram model using serum Club cell secretory protein 16 to predict prognosis and acute exacerbation in patients with idiopathic pulmonary fibrosis.
- Isorhapontigenin alleviates pulmonary fibrosis by inhibiting oxidative stress-induced senescence via STAT3/PRDX2 signals in alveolar epithelial cells.
- Air pollution exposure modes, smoking and genetic risk with chronic respiratory diseases: a prospective study.
- Serum cholesterol levels predict the survival in patients with idiopathic pulmonary fibrosis: A long-term follow up study.
- The potential lipid biomarker 5-HETE for acute exacerbation identified by metabolomics in patients with idiopathic pulmonary fibrosis.
- Identifying TNFSF4low-MSCs superiorly treating idiopathic pulmonary fibrosis through Tregs differentiation modulation.
- Novel 3D-based deep learning for classification of acute exacerbation of idiopathic pulmonary fibrosis using high-resolution CT.
- Gene expression profile analysis of severe influenza-based modulation of idiopathic pulmonary fibrosis.
- HE4-based nomogram for predicting overall survival in patients with idiopathic pulmonary fibrosis: construction and validation.
- The gene expression of CALD1, CDH2, and POSTN in fibroblast are related to idiopathic pulmonary fibrosis.
- PGC-1α regulates endoplasmic reticulum stress in IPF-derived fibroblasts.
- Shared biomarkers and mechanisms in idiopathic pulmonary fibrosis and non-small cell lung cancer.
- Exosomal circRNAs in the plasma serve as novel biomarkers for IPF diagnosis and progression prediction.
- Senescent lung-resident mesenchymal stem cells drive pulmonary fibrogenesis through FGF-4/FOXM1 axis.
- Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
- Elevated serum mitochondrial DNA levels were associated with the progression and mortality in idiopathic pulmonary fibrosis.
- Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy.
- Assessment and Management of Cough in Idiopathic Pulmonary Fibrosis: A Narrative Review.
- Diagnostic finding on high-resolution computed tomography (HRCT) predicts a good response to pirfenidone in patients with idiopathic pulmonary fibrosis.
- Animal models of acute exacerbation of pulmonary fibrosis.
- KLF4 regulates TERT expression in alveolar epithelial cells in pulmonary fibrosis.
- Elevated Expression of Growth Differentiation Factor-15 Is Associated With Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
- Prognostic Role of NLR, PLR and MHR in Patients With Idiopathic Pulmonary Fibrosis.
- Human epididymis protein 4 is associated with severity and poor prognosis of connective tissue disease-associated interstitial lung disease with usual interstitial pneumonia pattern.
- Idiopathic pulmonary fibrosis associated with circulating autoantibodies: a Chinese cohort of a long-term follow-up study.
- Construction of potential idiopathic pulmonary fibrosis related microRNA and messenger RNA regulatory network.
- Protective function of interleukin-22 in pulmonary fibrosis.
- Idiopathic pleuroparenchymal fibroelastosis confirmed by pathology: a case report.
Earlier papers (2016–2020)22
- Prognostic Value of Serum Osteopontin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
- Correlation between serum bilirubin levels and the severity as well as the prognosis of idiopathic pulmonary fibrosis.
- Association of serum macrophage-mannose receptor CD206 with mortality in idiopathic pulmonary fibrosis.
- Associations of Serological Biomarkers of sICAM-1, IL-1β, MIF, and su-PAR with 3-Month Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
- Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis.
- Epithelial cell senescence induces pulmonary fibrosis through Nanog-mediated fibroblast activation.
- PTEN loss regulates alveolar epithelial cell senescence in pulmonary fibrosis depending on Akt activation.
- Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-κB activation.
- Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.
- Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs. possible usual interstitial pneumonitis pattern.
- A long-term retrospective study of patients with biopsy-proven cryptogenic organizing pneumonia.
- Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
- Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis.
- The relationship between MUC5B promoter, TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort.
- Clinical features, risk factors, and outcomes of patients with interstitial pneumonia with autoimmune features: a population-based study.
- M2 macrophages induce EMT through the TGF-β/Smad2 signaling pathway.
- Radial Probe Endobronchial Ultrasound-guided Lung Biopsy for Histopathological Diagnosis of Cryptogenic Organizing Pneumonia.
- [Pulmonary intravascular large B-cell lymphomamanifesting as interstitial pneumonias: report of 2 cases and review of literature].
- Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis.
- Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
- Elevated sL1-CAM levels in BALF and serum of IPF patients.
- Telomere length and survival in IPF patients - Reply.
All its trials on ClinicalTrials.gov, any status11
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Nanjing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Nanjing for Fabry disease85 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Nanjing for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
Other diseases
IgA nephropathy
IgA 肾病Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Nanjing for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- B cell-derived exosomal tRNA-Pro-TGG served as a non-invasive biomarker and mediator of inflammation in progressive IgA nephropathy.
- Hydroxychloroquine blood concentrations and effects in Chinese patients with IgA nephropathy.
- Early reduction in total cholesterol to high-density lipoprotein cholesterol ratio predicts hydroxychloroquine efficacy in treating IgA nephropathy.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Osteogenesis imperfecta
成骨不全症Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Nanjing for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Nanjing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)3
- Trehalose reduces bone loss in experimental biliary cirrhosis rats via ERK phosphorylation regulation by enhancing autophagosome formation.
- Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9.
- Association between primary biliary cholangitis and osteoporosis: meta-analysis.
All its trials on ClinicalTrials.gov, any status2
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Nanjing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led no English-language PubMed papers on inherited epidermolysis bullosa in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Nanjing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Hereditary angioedema
遗传性血管性水肿Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Nanjing for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
南京鼓楼医院
Nanjing Drum Tower Hospital
南京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Comprehensive Cancer Centre of Drum Tower Hospital; Drum Tower Hospital; Affiliated Drum Tower Hospital of Nanjing University Medical School; Comprehensive Cancer Centre of Nanjing Drum Tower Hospital; Affiliated Drum Tower Hospital; Affiliated Drum Tower Hospital of Nanjing University; Nanjing Drum Tower Hospital Clinical College of Jiangsu University; Taikang Xianlin Drum Tower Hospital